Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets

Brii and Joincare Group sign licence agreement for BRII-693

Brii Biosciences and Joincare Pharmaceutical have signed a licence and technology transfer agreement for BRII-693 for MDR/XDR infections.

Brii Biosciences announces licensing agreement with Joincare Group for BRII-693 in Greater China

DURHAM, N.C. and BEIJING, July 3, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd ("Joincare Group"). Joincare Group will obtain an exclusive license…

Breakthrough Antibiotic BRII-693 Gets Major Boost: Brii Bio Partners With Joincare to Combat Drug-Resistant Infections

Novel antibiotic shows promising Phase 1 results against deadly drug-resistant infections. Exclusive China licensing deal accelerates path to market. See development plans.